Vasculitis: Publications of the GUSTO study

• Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study. Christ L, Seitz L, Scholz G, Sarbu AC, Amsler J, Bütikofer L, Tappeiner C, Kollert F, Reichenbach S, Villiger PM. Lancet Rheumatol. 2021 Sep;3(9):e619-e626. doi: 10.1016/S2665-9913(21)00152-1.
• Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis. Seitz L, Christ L, Lötscher F, Scholz G, Sarbu AC, Bütikofer L, Kollert F, Schmidt WA, Reichenbach S, Villiger PM. Rheumatology (Oxford). 2021 Nov 3;60(11):5052-5059. doi: 10.1093/rheumatology/keab484.
• Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial). Christ L, Gloor AD, Kollert F, Gaber T, Buttgereit F, Reichenbach S, Villiger PM. Front Immunol. 2023 May 23;14:1165758. doi: 10.3389/fimmu.2023.1165758.
• Serum protein profiling reveals distinct patient clusters in giant cell arteritis. Zingg F, Ryser FS, Gloor AD, Polysopoulos C, Villiger PM, Maurer B, Christ L. Rheumatology (Oxford). 2024 Oct 1;63(10):2887-2896. doi: 10.1093/rheumatology/keae072
• Magnetic resonance imaging to monitor disease activity in giant cell arteritis treated with ultra-short glucocorticoids and tocilizumab. Christ L, Bonel HM, Cullmann JL, Seitz L, Bütikofer L, Wagner F, Villiger PM. Rheumatology (Oxford). 2025 Apr 1;64(4):2059-2067. doi: 10.1093/rheumatology/keae378
• Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three year follow-up. Christ L, Seitz L, Scholz G, Bütikofer L, Kollert F, Reichenbach S, Villiger PM. Rheumatology (Oxford). 2025 Jun 6:keaf317. doi: 10.1093/rheumatology/keaf317. Online ahead of print.PMID: 40478774